Regeneron Pharmaceuticals Stock News

Biotech stocks to check out in the stock market today.

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s

TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET Company Participants Dr. Len Schleifer - President and Chief Executive Officer Ryan Cro

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Brook Jennings - Vice Pres

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is mor

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer –

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron s

The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exceptions to this trend.